As Eliquis Sales Lag, Bristol/Pfizer Take Action
This article was originally published in The Pink Sheet Daily
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.
You may also be interested in...
Recent Phase III releases include data for Actavis’ ceftazidime/avibactam for gram-negative abdominal infections and Baxter’s long-acting Factor VIII hemophilia drug BAX 855. GSK’s fluticasone approved for asthma and Bristol/Pfizer’s Eliquis expands labeling.
Business development is a top priority for Bristol, management said during the company’s second quarter earnings call, and the focus is on expanding in immuno-oncology portfolio and other core therapeutic areas.
Pfizer and Bristol-Myers Squibb’s Eliquis is now approved for a new use after orthopedic surgery. In competition with the broadly labeled Xarelto and Boehringer’s Pradaxa, Eliquis had a slower than expected launch, but has been performing better recently.